TEMPI Syndrome With Progressive Telangiectasias Associated With Pulmonary Deterioration

JAMA Dermatol. 2020 Dec 1;156(12):1379-1380. doi: 10.1001/jamadermatol.2020.2668.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Angiogenesis Inhibitors / administration & dosage
  • Antibodies, Monoclonal / administration & dosage
  • Bortezomib / administration & dosage
  • Drug Therapy, Combination / methods
  • Humans
  • Lenalidomide / administration & dosage
  • Lung / blood supply
  • Male
  • Middle Aged
  • Paraproteinemias / complications*
  • Paraproteinemias / diagnosis
  • Paraproteinemias / drug therapy
  • Polycythemia / complications*
  • Polycythemia / diagnosis
  • Polycythemia / drug therapy
  • Respiratory Insufficiency / etiology*
  • Syndrome
  • Telangiectasis / complications*
  • Telangiectasis / diagnosis
  • Telangiectasis / drug therapy

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • daratumumab
  • Bortezomib
  • Lenalidomide